Stay updated on Safety Tolerance Efficacy in IPF Clinical Trial
Sign up to get notified when there's something new on the Safety Tolerance Efficacy in IPF Clinical Trial page.

Latest updates to the Safety Tolerance Efficacy in IPF Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added to the page history. The notice about a lapse in government funding and the previous Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding notice about potential data inaccuracy and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a Show glossary option and minor wording/casing changes for QC labels (Last Update Submitted that Met QC Criteria vs Last Update Submitted that met QC Criteria), along with the No FEAR Act Data labeling. The Revision was updated from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check35 days agoChange DetectedCore study content and metadata were removed, including pamrevlumab, Idiopathic Pulmonary Fibrosis, related MeSH terms, and key study descriptions. This affects the communication of the study's purpose and details.SummaryDifference16%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page; this is a minor maintenance update that does not alter study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA consolidated 'Locations' section lists participating sites by state, and the previous separate per-state location headers have been removed, resulting in a new layout for site information.SummaryDifference2%

Stay in the know with updates to Safety Tolerance Efficacy in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Tolerance Efficacy in IPF Clinical Trial page.